SVRA Savara, Inc.
$5.30▼ -0.38%
Healthcare
Other
After hours
$5.30▲ +0.00%
Sep 11, 7:30 PM ET
Volume 1.06M
Avg Volume (10D) 1.33M
Key Metrics & Fundamentals
Market Cap
$1.09B
P/E Ratio
–
Div Yield
–%
52W Range
3.34 - 7.01
% vs 50 MA
-5.30%
% vs 200 MA
-5.35%
RSI-14
43.8
MACD Histogram
-0.0100
Beta (1Y vs SPY)
1.30
Free Cash Flow
-$29.97M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$40.77M
COGS
–
Operating Exp
$40.97M
Operating Income
-$40.97M
EBIT
-$40.97M
Pretax Income
-$40.23M
Net Income
-$40.23M
EPS (Diluted)
-0.16
Price & Volume History
Loading chart…
Recent News
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026
Business Wire · Aug 24, 2026 8:05 PM
Savara Announces New Employment Inducement Grant
Business Wire · Aug 20, 2026 8:05 PM
Savara Reports Second Quarter 2026 Financial Results and Provides Business Update
Business Wire · Aug 11, 2026 8:05 PM
What Insmed Stock's Premium Is Actually Buying
Trefis · Aug 7, 2026 3:39 PM
Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041
Business Wire · Jul 30, 2026 12:05 PM
Here's Why You Should Add Savara Stock to Your Portfolio Now
Zacks · Jul 22, 2026 1:21 PM
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
GlobeNewswire · Jun 30, 2026 11:30 AM
What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline
Motley Fool · Jun 27, 2026 3:34 PM
Savara Insider Sold Shares Worth $2,241,432, According to a Recent SEC Filing
MT Newswires · Jun 23, 2026 8:04 AM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See SVRA's money flow as a full page
Social Sentiment
Avg +0.80 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.